Madrigal Pharmaceuticals MDGL Insider Ownership

Updated Oct 10, 2026

Over the past year, MDGL insiders sold $81.46 million of stock (154.94K shares) on the open market and bought none.

• A count shows 9 insiders selling MDGL stock on the open market over the past 12 months and none buying.
• Paul A. Friedman (Director) was MDGL's largest open-market seller in the past 12 months, with $26.64 million of sales (49.56K shares); the latest was on January 9, 2026.
• Madrigal Pharmaceuticals' latest insider trade on the open market was a sale of 5.22K shares for $2.83 million by William John Sibold (President and CEO) on September 11, 2026.
• Outside the open market, Madrigal Pharmaceuticals insiders received 38.31K shares in stock awards, acquired 222.65K shares through option exercises and conversions and gave away 5.46K shares as gifts over the past 12 months.
• Business Quant data puts insider holdings in MDGL at 3.91Mn shares across insiders' latest Form 4 filings, up 0.93% from 3.88Mn shares at the end of Q2 2026 and up 4.08% from 3.76Mn shares at the end of Q3 2025.
• Madrigal Pharmaceuticals insiders hold 1.27Mn shares directly (32.57% of their total) and 2.64Mn shares (67.43%) indirectly, through entities such as trusts and partnerships.
• Per Business Quant, 17 insiders of MDGL hold shares, counting officers, directors and 10% owners who have filed a Form 4 in the past two years.
• Madrigal Pharmaceuticals' three largest insider shareholders, based on their latest Form 4 filings, are Baker Bros. Advisors LP (Director, 1.95Mn shares), Rebecca Taub (Director, 1.11Mn shares) and Fred B. Craves (Director, 383.55K shares).
• The holding of Baker Bros. Advisors LP makes up 49.82% of all shares held by Madrigal Pharmaceuticals insiders.
• Institutions held 80.92% of Madrigal Pharmaceuticals' outstanding shares in their Q2 2026 13F filings, insiders about 13.42% based on their latest Form 4 filings, and other investors, including the public, the remaining 5.66%.
• In the past year, 15 insiders of Madrigal Pharmaceuticals submitted 39 Form 4 filings reporting trades, awards or other transactions.
• These insider figures for Madrigal Pharmaceuticals are based on Form 4 filings through September 11, 2026.